Passage Bio Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Passage Bio sono diminuiti a un tasso annuo medio di -4.9%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 19.1%.

Informazioni chiave

-4.9%

Tasso di crescita degli utili

35.2%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-94.6%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

May 03

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Jan 04

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28

U.K. authorizes Passage Bio's PBGM01 trial

Dec 10

Passage Bio (PASG) Investor Presentation - Slideshow

Nov 16

Passage Bio EPS beats by $0.13

Nov 10

Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

Oct 28

Ripartizione dei ricavi e delle spese

Come Passage Bio guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:PASG Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	-69	27	43
30 Jun 24	-77	39	49
31 Mar 24	-84	40	56
31 Dec 23	-102	42	61
30 Sep 23	-112	42	65
30 Jun 23	-112	33	65
31 Mar 23	-128	38	74
31 Dec 22	-136	46	84
30 Sep 22	-160	56	101
30 Jun 22	-180	60	113
31 Mar 22	-189	63	119
31 Dec 21	-185	60	118
30 Sep 21	-173	53	113
30 Jun 21	-155	46	107
31 Mar 21	-134	38	94
31 Dec 20	-112	30	82
30 Sep 20	-86	24	64
30 Jun 20	-69	17	53
31 Mar 20	-56	11	40
31 Dec 19	-46	7	30
30 Sep 19	-38	4	26

Guadagni di qualità: PASG al momento non è redditizia.

Margine di profitto in crescita: PASG al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: PASG non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 4.9% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di PASG nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: PASG non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: PASG ha un Return on Equity negativo ( -94.61% ), in quanto al momento non è redditizio.

Passage Bio Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio, Inc. to Report Q4, 2020 Results on Mar 03, 2021

Passage Bio, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Passage Bio, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Recent updates

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

New minor risk - Shareholder dilution

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Price target increased by 27% to US$7.00

Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Price target decreased by 23% to US$5.40

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Price target decreased by 20% to US$7.00

Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study

Passage Bio, Inc. Announces Executive Changes

Price target increased by 9.9% to US$8.17

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Price target increased by 9.3% to US$8.33

Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

High number of new directors

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. Announces Executive Changes

Passage appoints William Chou CEO

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio GAAP EPS of -$0.73 beats by $0.09

High number of new directors

Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2000 Dynamic Index

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio, Inc. Announces Management Changes

Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Passage Bio, Inc., Annual General Meeting, May 26, 2022

Passage Bio: Worth Keeping An Eye On

Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio Presents New Interim Clinical Data for Patients with Gm1 Gangliosidosis in Imagine-1 Study At 2022 Worldsymposium

Price target decreased to US$23.38

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2500 Growth Index

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Independent Director Patrick Heron has left the company

Chief Financial Officer has left the company

Chief Medical Officer has left the company

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

Chief Medical Officer notifies of intention to sell stock

Passage Bio, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Passage Bio, Inc. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day low: US$18.13

Passage Bio, Inc. Announces Board Changes

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations